On November 5, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that four abstracts relating to the Company’s lead product candidate, rigosertib, were accepted for presentation at the 60th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition in San Diego, California, which takes place December 1-4, 2018 (Press release, Onconova, NOV 5, 2018, View Source [SID1234530731]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ORAL PRESENTATION:
Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Novel Therapeutics I
Date: Saturday, December 1, 2018
Session Time: 4:00 – 5:30 PM
Presentation Time: ORAL SESSION 4:15 PM PST
Room: Manchester Grand Hyatt San Diego, Grand Hall A
Presenter: Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
POSTER PRESENTATIONS:
1) Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
Date: Saturday, December 1, 2018
Presentation Time: 6:15 – 8:15 PM
Location: San Diego Convention Center, Hall GH
Presenter: John Roboz, PhD, Icahn School of Medicine at Mount Sinai, New York, NY
2) Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:00 – 8:00 PM
Location: San Diego Convention Center, Hall GH
Presenter: Manoj Maniar, PhD, Onconova Therapeutics, Inc., Newtown, PA
3) Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Poster III
Date: Monday, December 3, 2018
Presentation Time: 6:00 – 8:00 PM
Location: San Diego Convention Center, Hall GH
Presenter: David Taft, PhD, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY